At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 44 enrolled
Drug / intervention
Omega-3 SPM™ softgeldietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Influence of an Omega-3 SPM Supplement on Quality of Life
In Brief
A Early Phase 1 clinical trial evaluating Omega-3 SPM™ softgel for Chronic Pain. Completed, enrolled 44 participants across 1 site.
Detailed Summary
This prospective, non-randomized, open-label study will assess if taking an Omega-3 SPM™ soft gel supplement for four weeks will increase the quality of life in adults with chronic pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pain
CountriesUnited States
CollaboratorsMetagenics, Inc.
Timeline
Early Ph 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
First PostedFeb 2016
Primary CompletionJul 2016
TodayJul 2026
First PostedFeb 17, 2016
Enrollment StartJan 1, 2016
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.4 years ago
Interventions
Omega-3 SPM™ softgeldietary
This four week, prospective, non-randomized, open-label study is assessing the impact on quality of life from taking an Omega-3 SPM™ softgel supplement in adults with pain symptoms at screening of 4 or higher on the PROMIS-43 Profile - Pain Intensity subscale.